Zevra Therapeutics (ZVRA) Enterprise Value (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Enterprise Value came in at -$200.6 million in Q1 2026, down 220.31% YoY from $166.7 million in Q1 2025, and down 5.03% on a QoQ basis from -$191.0 million in Q4 2025.
Zevra Therapeutics (ZVRA) Enterprise Value (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Enterprise Value data on file, last reported at -$200.6 million in Q1 2026.
- Quarterly Enterprise Value fell 220.31% year-over-year to -$200.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$200.6 million (down 220.31% YoY) and the FY2025 annual result came in at -$191.0 million, down 174.85% from the prior year.
- Enterprise Value slipped to -$200.6 million in Q1 2026, from -$191.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$479000.0 in Q2 2023 to a low of -$202.6 million in Q2 2025.
- A 5-year average of -$92.6 million and a median of -$68.6 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 99.38% — and 2024, when it plunged 10183.51%.
- Tracing ZVRA's Enterprise Value over 5 years: stood at -$65.9 million in 2022, then fell by 2.71% to -$67.7 million in 2023, then declined by 2.6% to -$69.5 million in 2024, then slumped by 174.85% to -$191.0 million in 2025, then fell by 5.03% to -$200.6 million in 2026.
- The last three Enterprise Value figures came in at -$200.6 million (Q1 2026), -$191.0 million (Q4 2025), and -$199.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | -221.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -221.57 Mn |
| Mar 31, 2026 | -200.62 Mn |
| Dec 31, 2025 | -191.01 Mn |
| Sep 30, 2025 | -199.51 Mn |
| Jun 30, 2025 | -202.61 Mn |
| Mar 31, 2025 | -62.63 Mn |
| Dec 31, 2024 | -69.50 Mn |
| Sep 30, 2024 | -89.38 Mn |
| Jun 30, 2024 | -49.26 Mn |
| Mar 31, 2024 | -52.72 Mn |
| Dec 31, 2023 | -67.74 Mn |
| Sep 30, 2023 | -43.27 Mn |
| Jun 30, 2023 | -479,000.00 |
| Mar 31, 2023 | -40.18 Mn |
| Dec 31, 2022 | -65.95 Mn |
| Sep 30, 2022 | -70.06 Mn |
| Jun 30, 2022 | -76.78 Mn |
| Dec 31, 2021 | -112.35 Mn |
| Sep 30, 2021 | -131.50 Mn |
| Jun 30, 2021 | -132.30 Mn |